Barclays PLC Grows Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Barclays PLC raised its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 4.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 423,221 shares of the company's stock after purchasing an additional 17,744 shares during the quarter. Barclays PLC owned approximately 0.92% of Pacira BioSciences worth $7,972,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of PCRX. Sterling Capital Management LLC increased its stake in Pacira BioSciences by 779.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock valued at $26,000 after purchasing an additional 1,208 shares in the last quarter. Caitlin John LLC lifted its holdings in Pacira BioSciences by 1,850.0% during the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company's stock valued at $35,000 after purchasing an additional 1,776 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after purchasing an additional 2,749 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock valued at $68,000 after acquiring an additional 513 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Pacira BioSciences by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock worth $184,000 after purchasing an additional 918 shares during the period. Institutional investors and hedge funds own 99.73% of the company's stock.

Pacira BioSciences Stock Down 1.0 %

Shares of Pacira BioSciences stock traded down $0.27 during trading on Tuesday, hitting $26.87. The company's stock had a trading volume of 60,892 shares, compared to its average volume of 979,083. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $31.67. The company has a market capitalization of $1.24 billion, a PE ratio of -13.24 and a beta of 0.71. The company has a fifty day simple moving average of $24.52 and a two-hundred day simple moving average of $21.61. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25.

Wall Street Analyst Weigh In

PCRX has been the subject of a number of recent research reports. HC Wainwright boosted their target price on Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 target price on shares of Pacira BioSciences in a report on Tuesday, April 8th. Barclays raised their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. Truist Financial raised Pacira BioSciences from a "sell" rating to a "hold" rating and boosted their target price for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $26.67.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.